{
    "id": "3383dbe6-8796-a02d-e063-6294a90a4a5c",
    "indications": {
        "text": "metformin hydrochloride extended-release tablets indicated adjunct diet exercise improve glycemic control adults type 2 diabetes mellitus .",
        "doid_entities": [
            {
                "text": "type 2 diabetes mellitus (DOID:9352)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9352"
            },
            {
                "text": "diabetes (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "adult metformin hydrochloride extended-release tablets : swallow metformin hydrochloride extended-release tablets whole never crush , cut chew ( 2.1 ) starting dose : 500 mg orally daily evening meal ( 2.1 ) increase dose increments 500 mg weekly , maximum 2000 mg daily evening meal ( 2.1 ) patients receiving metformin hydrochloride tablets may switched metformin hydrochloride extended-release tablets daily total daily dose , 2000 mg daily ( 2.1 ) renal impairment : prior initiation , assess renal function estimated glomerular filtration rate ( egfr ) ( 2.3 ) patients egfr 30 ml/minute/1.73 2 ( 2.3 ) initiation recommended patients egfr 30 45 ml/minute/1.73 2 ( 2.3 ) assess risk/benefit continuing egfr falls 45 ml/ minute/1.73 2 ( 2.3 ) discontinue egfr falls 30 ml/minute/1.73 2 ( 2.3 ) discontinuation iodinated contrast imaging procedures : metformin hydrochloride extended-release tablets may need discontinued time , prior , iodinated contrast imaging procedures ( 2.4 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "table 13 : metformin hydrochloride extended-release tablets , usp available strengths , units , appearance metformin hydrochloride extended-release tablets , usp 500 mg bottles 100 ndc 69315-410-01 white white capsule shaped , biconvex , beveled edge tablet , occasionally mottled appearance , debossed `` 001 `` one side plain side . bottles 500 ndc 69315-410-05",
    "adverseReactions": "metformin hydrochloride extended-release tablets contraindicated patients : severe renal impairment ( egfr 30 ml/min/1.73 2 ) [ ( 5.1 ) ] . hypersensitivity metformin . acute chronic metabolic acidosis , including diabetic ketoacidosis , without coma .",
    "ingredients": [
        {
            "name": "CARBOXYMETHYLCELLULOSE SODIUM",
            "code": "K679OBS311",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_85146"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "METFORMIN HYDROCHLORIDE",
            "code": "786Z46389E",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6802"
        }
    ],
    "organization": "Leading Pharma, LLC",
    "name": "METFORMIN HYDROCHLORIDE",
    "effectiveTime": "20250424",
    "indications_original": "Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.",
    "contraindications_original": "Adult Dosage for Metformin Hydrochloride Extended-Release Tablets: Swallow metformin hydrochloride extended-release tablets whole and never crush, cut or chew (2.1 ) Starting dose: 500 mg orally once daily with the evening meal ( 2.1 ) Increase the dose in increments of 500 mg weekly, up to a maximum of 2000 mg once daily with the evening meal ( 2.1 ) Patients receiving metformin hydrochloride tablets may be switched to metformin hydrochloride extended-release tablets once daily at the same total daily dose, up to 2000 mg once daily ( 2.1 ) Renal Impairment: Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) ( 2.3 ) Do not use in patients with eGFR below 30 mL/minute/1.73 m 2 ( 2.3 ) Initiation is not recommended in patients with eGFR between 30 to 45 mL/minute/1.73 m 2 ( 2.3 ) Assess risk/benefit of continuing if eGFR falls below 45 mL/ minute/1.73 m 2 ( 2.3) Discontinue if eGFR falls below 30 mL/minute/1.73 m 2 ( 2.3 ) Discontinuation for Iodinated Contrast Imaging Procedures: Metformin hydrochloride extended-release tablets may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures ( 2.4 )",
    "warningsAndPrecautions_original": "Table 13: Metformin Hydrochloride Extended-Release Tablets, USP Available Strengths, Units, and appearance\n                           \n                           \n                           \n                           \n                           \n                              \n                                 \n                                    Metformin Hydrochloride Extended-Release Tablets, USP\n                                 \n                              \n                              \n                                 500 mg\n                                 Bottles of 100\n                                 NDC 69315-410-01\n                                 White to off white capsule shaped, biconvex, beveled edge tablet, with occasionally mottled \n     \n                                      appearance, debossed with \"\n    \n     001\" on one side and plain on other side.\n   \n    \n                              \n                              \n                                 Bottles of 500\n                                 NDC 69315-410-05",
    "adverseReactions_original": "Metformin hydrochloride extended-release tablets are contraindicated in patients with:\n                  \n                     \u00a0 Severe renal impairment (eGFR below 30 mL/min/1.73 m\n  \n   2) [\n  \n   \n                           see Warnings and Precautions (5.1)\n                        ].\n \n  \n                     \u00a0 Hypersensitivity to metformin.\n                     \u00a0 Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.",
    "drug": [
        {
            "name": "METFORMIN HYDROCHLORIDE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6802"
        }
    ]
}